TD Cowen analyst Josh Jennings has maintained their neutral stance on EW stock, giving a Hold rating on April 16.
Josh Jennings has given his Hold rating due to a combination of factors influencing Edwards Lifesciences. The company reported better-than-expected results in the first quarter, with both revenue and earnings surpassing projections. Notably, the Transcatheter Aortic Valve Replacement (TAVR) segment showed solid growth, and Edwards maintained its global market share. However, despite these positive results, the company faces challenges such as tariff and M&A-related headwinds, which could impact future performance.
Additionally, while the Transcatheter Mitral and Tricuspid Therapies (TMTT) segment also exceeded expectations, the overall growth in the Surgical segment was modest. The company’s ability to sustain its competitive positioning and pricing stability globally is crucial. Given these mixed signals, Jennings believes that a Hold rating is appropriate, suggesting that investors may want to wait for clearer indications of sustained growth before making further investment decisions.
Jennings covers the Healthcare sector, focusing on stocks such as Abbott Laboratories, Boston Scientific, and Edwards Lifesciences. According to TipRanks, Jennings has an average return of 0.2% and a 45.47% success rate on recommended stocks.
In another report released on April 16, Leerink Partners also reiterated a Hold rating on the stock with a $77.00 price target.